Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Active | ||
| Glatect | Glatiramer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex | Reimburse with clinical criteria and/or conditions | Active | ||
| Afinitor | Everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | Do not list | Complete | ||
| Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lenvima | Lenvatinib | Renal Cell Carcinoma (RCC) | Do not reimburse | Complete | ||
| Keytruda | pembrolizumab | Renal cell carcinoma, adjuvant | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Resectable Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 25, 2024